What is it about?
We describe a practical implementation of the Lugano criteria for assessment of lymphoma in clinical trials.
Featured Image
Why is it important?
The Lugano criteria have emerged as an important and valuabe methodology for response assessment in clinical drug trials for lymphoma treatments. We developed a practical implementation of the method and demonstrated the consistency of its results by comparing the assessments of three independent reviewers.
Perspectives
We successfully demonstrated that our approach to the implementation of the Lugano method resulted in reliably consistent response assessments among independent reviewers of imaging data for clinical trials.
Dr John Wolodzko
Read the Original
This page is a summary of: Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials, Drug Design Development and Therapy, June 2017, Dove Medical Press,
DOI: 10.2147/dddt.s136988.
You can read the full text:
Contributors
The following have contributed to this page
